Sec Form 3 Filing - Zeevi Mali @ BioLineRx Ltd. - 2026-03-18

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Zeevi Mali 2. Issuer Name and Ticker or Trading Symbol BioLineRx Ltd. [ BLRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) BIOLINERX LTD., 2 HAMA'AYAN STREET 3. Date of Earliest Transaction (MM/DD/YY) 03/18/2026 (Street) MODII'N7177871 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares, 0.1 NIS per share 1,311,000 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) ( 1 ) ( 2 ) $ 0.264 10/09/2017 10/09/2026 Ordinary Shares 43,800 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 3 ) $ 0.27 02/21/2018 02/21/2027 Ordinary Shares 126,600 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 4 ) $ 0.287 12/26/2018 12/26/2027 Ordinary Shares 280,200 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 5 ) $ 0.276 03/25/2020 03/25/2029 Ordinary Shares 454,800 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 6 ) $ 0.15 11/17/2021 11/17/2030 Ordinary Shares 704,400 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 7 ) $ 0.101 03/15/2023 03/15/2032 Ordinary Shares 1,006,800 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 8 ) $ 0.045 03/21/2024 03/21/2033 Ordinary Shares 1,078,800 ( 10 ) D Employee Stock Option (Right to Buy) ( 1 ) ( 9 ) $ 0.006 11/19/2026 11/19/2035 Ordinary Shares 13,680,000 ( 10 ) D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Zeevi Mali BIOLINERX LTD. 2 HAMA'AYAN STREET MODII'N7177871 Chief Financial Officer Signatures /s/ Mali Zeevi 03/18/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Options granted under the 2003 Amended and Restated Share Incentive Plan. ( 2 )The grant date of this grant is October 9, 2016. This option grant is fully vested as of this date. ( 3 )The grant date of this grant is February 21, 2017. This option grant is fully vested as of this date. ( 4 )The grant date of this grant is December 26, 2017. This option grant is fully vested as of this date. ( 5 )The grant date of this grant is March 25, 2019. This option grant is fully vested as of this date. ( 6 )The grant date of this grant is November 17, 2020. This option grant is fully vested as of this date. ( 7 )The grant date of this grant is March 15, 2022. This option grant is fully vested as of this date. ( 8 )The grant date of this grant is March 21, 2023. As of this date, 741,600 of the options were vested as of the date of appointment. The remaining 337,200 options will vest in 5 equal quarterly installments, subt to the Reporting Person's continued service to the Issuer as of each vesting date. ( 9 )The grant date of this grant is November 19, 2025. As of this date, none of the options were vested. As of the grant date 3,420,000 options have a one-year cliff and the remaining 10,260,000 options will vest in 12 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. ( 10 )To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.